Equities analysts expect that Repligen Co. (NASDAQ:RGEN) will report $0.18 earnings per share for the current quarter, Zacks reports. Seven analysts have made estimates for Repligen’s earnings. The highest EPS estimate is $0.20 and the lowest is $0.17. Repligen posted earnings per share of $0.21 during the same quarter last year, which would suggest a negative year over year growth rate of 14.3%. The business is scheduled to report its next earnings results on Thursday, February 20th.
On average, analysts expect that Repligen will report full year earnings of $1.03 per share for the current fiscal year, with EPS estimates ranging from $1.02 to $1.04. For the next year, analysts anticipate that the company will report earnings of $1.11 per share, with EPS estimates ranging from $0.97 to $1.22. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Repligen.
Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, October 31st. The biotechnology company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.19 by $0.07. Repligen had a return on equity of 6.50% and a net margin of 9.28%. The company had revenue of $69.45 million for the quarter, compared to the consensus estimate of $66.10 million. During the same quarter last year, the company posted $0.20 earnings per share. The company’s revenue for the quarter was up 40.2% compared to the same quarter last year.
RGEN stock traded up $0.82 during midday trading on Wednesday, hitting $88.61. 313,800 shares of the company traded hands, compared to its average volume of 494,767. Repligen has a twelve month low of $48.26 and a twelve month high of $99.25. The company has a quick ratio of 14.70, a current ratio of 16.03 and a debt-to-equity ratio of 0.25. The business has a 50 day simple moving average of $83.03 and a 200-day simple moving average of $82.85. The stock has a market capitalization of $4.61 billion, a price-to-earnings ratio of 121.38, a price-to-earnings-growth ratio of 4.35 and a beta of 1.15.
In other news, CEO Anthony Hunt sold 3,600 shares of the firm’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $82.89, for a total value of $298,404.00. Following the sale, the chief executive officer now owns 223,013 shares in the company, valued at $18,485,547.57. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 1.70% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Sheets Smith Wealth Management grew its stake in shares of Repligen by 2.2% in the third quarter. Sheets Smith Wealth Management now owns 6,514 shares of the biotechnology company’s stock worth $500,000 after acquiring an additional 141 shares during the last quarter. Pitcairn Co. lifted its position in Repligen by 7.0% in the second quarter. Pitcairn Co. now owns 3,769 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 245 shares during the period. Voya Financial Advisors Inc. lifted its position in Repligen by 8.3% in the third quarter. Voya Financial Advisors Inc. now owns 3,874 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 297 shares during the period. Oregon Public Employees Retirement Fund lifted its position in Repligen by 2.0% in the second quarter. Oregon Public Employees Retirement Fund now owns 15,417 shares of the biotechnology company’s stock worth $1,325,000 after purchasing an additional 300 shares during the period. Finally, State Board of Administration of Florida Retirement System lifted its position in Repligen by 1.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 24,278 shares of the biotechnology company’s stock worth $2,087,000 after purchasing an additional 310 shares during the period. Institutional investors and hedge funds own 85.54% of the company’s stock.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
See Also: What is systematic risk?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.